Biogen INC BIOGEN INC ORD SHS
Biogen INC BIOGEN INC ORD SHS/ US09062X1037 /
0R1B
10.09.2024 19:49:21
|
Zm.
-
|
Wolumen |
Bid06:00:08 |
Ask06:00:08 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
199,86USD
|
-
|
819 Obrót: 163 048,87 |
-Wolumen Bid: - |
-Wolumen Ask: - |
29,23 mldUSD |
- |
25,02 |
Opis działalności
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Zarząd & Rada nadzorcza
CEO |
Christopher A. Viehbacher |
Zarząd |
Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
Rada nadzorcza |
Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher |
Dane firmy
Nazwa: |
Biogen Inc. |
Adres: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
Telefon: |
+1 781-464-2000 |
Fax: |
+1-617-679-2617 |
E-mail: |
-
|
Internet: |
www.biogen.com |
Przemysł: |
Biotechnologia |
Sektor: |
Biotechnologia |
Podsektor: |
Biotechnologia |
Koniec roku finansowego: |
31.12 |
Free float: |
72,20% |
Data IPO: |
- |
Relacje inwestorskie
Nazwa: |
Karen Jewell |
Telefon: |
781-464-2442 |
Fax: |
- |
E-mail: |
IR@biogenidec.com
|
Główni akcjonariusze
Inne |
|
48,93% |
PRIMECAP MANAGEMENT CO CA |
|
11,17% |
Vanguard Group |
|
9,90% |
BlackRock Inc. |
|
9,79% |
State Street Corporation |
|
4,77% |
"T. Rowe Price Investment Management, Inc." |
|
3,68% |
Wellington Management Group |
|
3,66% |
JP Morgan Chase & Co. |
|
3,44% |
GEODE CAPITAL MANAGEMENT LLC |
|
2,27% |
Inne |
|
2,40% |